This hypothesis proposes that the efficiency of pathological protein clearance is governed by the kinetic coupling between Hsp70 ATPase cycle velocity and CHIP-mediated ubiquitination rates. The mechanism centers on Parent A's core insight that chaperone disaggregation follows Michaelis-Menten kinetics, where Vmax represents the maximum velocity of the Hsp70/DNAJB1 system's ATP-dependent substrate processing. However, the critical innovation from Parent B is that substrate fate—refolding versus degradation—is determined by CHIP's ability to intercept Hsp70-bound substrates during specific phases of the ATPase cycle. When DNAJB1 delivers misfolded proteins to Hsp70 and stimulates ATP hydrolysis through its HPD motif, the resulting ADP-bound state creates a kinetic window where CHIP's TPR domain can bind to Hsp70's C-terminal EEVD motifs. The duration of this ADP-bound state, regulated by nucleotide exchange factors, determines whether CHIP's U-box domain has sufficient time to ubiquitinate the substrate before ATP binding triggers substrate release.

This hypothesis proposes that the efficiency of pathological protein clearance is governed by the kinetic coupling between Hsp70 ATPase cycle velocity and CHIP-mediated ubiquitination rates. The mechanism centers on Parent A's core insight that chaperone disaggregation follows Michaelis-Menten kinetics, where Vmax represents the maximum velocity of the Hsp70/DNAJB1 system's ATP-dependent substrate processing. However, the critical innovation from Parent B is that substrate fate—refolding versus degradation—is determined by CHIP's ability to intercept Hsp70-bound substrates during specific phases of the ATPase cycle. When DNAJB1 delivers misfolded proteins to Hsp70 and stimulates ATP hydrolysis through its HPD motif, the resulting ADP-bound state creates a kinetic window where CHIP's TPR domain can bind to Hsp70's C-terminal EEVD motifs. The duration of this ADP-bound state, regulated by nucleotide exchange factors, determines whether CHIP's U-box domain has sufficient time to ubiquitinate the substrate before ATP binding triggers substrate release. At high aggregate concentrations approaching the system's Vmax, the accelerated cycling overwhelms CHIP's ubiquitination kinetics, leading to substrate release and re-aggregation. Conversely, when aggregate levels remain below the kinetic threshold, slower ATP cycling allows complete CHIP-mediated ubiquitination and proteasomal targeting. This model predicts that therapeutic enhancement of either CHIP expression or NEF activity should shift the kinetic threshold, allowing higher aggregate loads to be efficiently cleared through the proteasome rather than accumulating as persistent seeds.